Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2019-04-22
- Last Posted Date
- 2022-09-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 101
- Registration Number
- NCT03922997
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing City, China
🇨🇳Sichuan Cancer Hospital, Chengdu City, China
🇨🇳Harbin Medical University Tumor Hospital; Department of Surgery; Pharmacy, Harbin, China
High-Risk Skin Cancers With Atezolizumab Plus NT-I7
- Conditions
- Interventions
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- NeoImmuneTech
- Target Recruit Count
- 31
- Registration Number
- NCT03901573
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Dana Farber, Boston, Massachusetts, United States
🇺🇸MGH, Boston, Massachusetts, United States
Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)
- Conditions
- Interventions
- First Posted Date
- 2019-03-29
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Fondazione Ricerca Traslazionale
- Target Recruit Count
- 206
- Registration Number
- NCT03896074
- Locations
- 🇮🇹
IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
🇮🇹AO Papardo, Messina, Italy
🇮🇹A.O. Per l' emergenza Cannizzaro, Catania, Italy
Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- Renske Altena
- Target Recruit Count
- 6
- Registration Number
- NCT03894007
- Locations
- 🇸🇪
Sahlgrenska universitetssjukhuset, Göteborg, Sweden
🇸🇪Skånes universitetssjukhus, Malmö, Sweden
🇸🇪Länssjukhuset Sundsvall, Sundsvall, Sweden
Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2021-07-26
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 4
- Registration Number
- NCT03892525
- Locations
- 🇫🇷
APHP - Hôpital Henri Mondor, Créteil, France
🇫🇷CHU de Rennes - Hôpital Pontchaillou, Rennes, France
🇫🇷CHU de Montpellier, Montpellier, France
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
- First Posted Date
- 2019-03-11
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 645
- Registration Number
- NCT03869190
- Locations
- 🇪🇸
START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid, Spain
🇪🇸Hospital Clinico Universitario de Valencia, Valencia, Spain
🇨🇳National Taiwan University Hospital, Yun-Lin Branch, Huwei Township, Taiwan
A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 47
- Registration Number
- NCT03866239
- Locations
- 🇫🇷
Centre Leon Berard; Departement Oncologie Medicale, Lyon, France
🇺🇸Stanford Comprehensive Cancer Center, Stanford, California, United States
🇪🇸START Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid, Spain
Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 28
- Registration Number
- NCT03853707
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 325
- Registration Number
- NCT03845166
- Locations
- 🇺🇸
Exelixis Clinical Site #84, Los Angeles, California, United States
🇺🇸Exelixis Clinical Site #71, Stanford, California, United States
🇺🇸Exelixis Clinical Site #85, Bronx, New York, United States
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 37
- Registration Number
- NCT03841110
- Locations
- 🇺🇸
Hackensack University Medical Center/John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.